Vitamin D dietary supplements can promote bone mineralization without changing phosphate levels or causing calcium to rise to unhealthy levels and form solid deposits in the kidneys. That finding, from a study in a mouse model of X‐linked hypophosphatemia (XLH), suggests that vitamin D supplements, when used alone or…
The International Osteoporosis Foundation (IOF) has given its first five Skeletal Rare Diseases Academy Awards to researchers working on rare bone disorders, including X‐linked hypophosphatemia (XLH). Selected by a panel of academy members, the awardees received a certificate along with a grant totaling $1,000 in recognition of…
Higher doses of phosphate and vitamin D supplements seem to reduce bone deformities in young people with hypophosphatemic rickets (HR), a Turkish nationwide study reports. However, such increased doses also may cause a disorder called nephrocalcinosis, in which the levels of calcium in the kidneys become abnormally…
Identifying and treating X‐linked hypophosphatemia (XLH) early is key to improving quality of life for people with the disorder, particularly in developing countries, a case report shows. The report, detailing a child in Columbia with this disease, also highlights the difficulties facing doctors and patients with rare disorders in poorer…
Approximately one third of children and young adults with X‐linked hypophosphatemia (XLH) are overweight or obese, a study has found. Lack of family history of XLH and longer treatment with phosphorus supplements were identified as risk factors for excessive weight gain in these patients. The study, “…
Treatment with Crysvita (burosumab) restores phosphate balance and improves bone mineralization in adults with X‐linked hypophosphatemia (XLH), a Phase 3 trial shows. The findings were reported in a study, “Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm,…
Get regular updates to your inbox.